Drug news
NICE provides limited recommendation for Pixuvri for NHL-Cell Therapeutics
NICE (The National Institute for Health and Care Excellence) has finally recommended Pixuvri (pixantrone)) from Cell Therapeutics for the treatment of aggressive non Hodgkins Lymphoma. The agency agreed that Pixuvri was cost effective in a limited group of patients being those who had previously been treated with MabThera(ritiximab) and those receiving third and fourth line therapy.